Defining and labeling disease-modifying treatments for Alzheimer's disease

Alzheimer's and Dementia

Volumn 5, Issue 5, 2009, Pages 406-418

  Cummings, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Biomarker; Clinical trial; Disease modification; Neuroprotection; Primary prevention; Tau; Treatment

Indexed keywords

ALENDRONIC ACID; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA1A INTERFERON; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; DIMEBON; ETANERCEPT; IBANDRONIC ACID; METHOTREXATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; PLACEBO; RISEDRONIC ACID; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID LEVEL; CLINICAL TRIAL; DISEASE COURSE; HUMAN; MULTIPLE SCLEROSIS; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE; TEMPORAL LOBE;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; ENDPOINT DETERMINATION; HUMANS; MAGNETIC RESONANCE IMAGING; PRIMARY PREVENTION; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 69949137832     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2008.12.003     Document Type: Article

References (63)

1. Doody R.S. We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug development. Alzheimers & Dementia 4 (2008) S21-S25
2. Knopman D. Finding potent drugs for Alzheimer's disease is more important than proving the drugs are disease modifying. Alzheimers & Dementia 2 (2006) 147-149
3. Mani R.B. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Stat Med 23 (2004) 305-314
4. Sampaio C. Alzheimer disease: disease modifying trials: where are we? where do we need to go? a reflective paper. J Nutr Health Aging 10 (2006) 113-115
5. Mohs R.C., Doody R.S., Morris J.C., Ieni J.R., Rogers S.L., Perdomo C.A., et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57 (2001) 481-488 Erratum in: Neurology 2001;57:1942
6. DeCarli C., Frisoni G.B., Clark C.M., Harvey D., Grundman M., Petersen R.C., et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol 64 (2007) 108-115
7. Vellas B., Andrieu S., Sampaio C., and Wilcock G. European Task Force group. Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 6 (2007) 56-62
8. Courtney C., Farrell D., Gray R., Hills R., Lynch L., Sellwood E., et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363 (2004) 2105-2115
9. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372 (2008) 216-223
10. Li G., Larson E.B., Sonnen J.A., Shofer J.B., Petrie E.C., Schantz A., et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 69 (2007) 878-885
11. Sparks D.L., Lemieux S.K., Haut M.W., Baxter L.C., Johnson S.C., Sparks L.M., et al. Hippocampal volume change in the Alzheimer disease cholesterol-lowering treatment trial. Cleve Clin J Med 75 (2008) S87-S93
12. Szekely C.A., Green R.C., Breitner J.C., Østbye T., Beiser A.S., Corrada M.M., et al. No advantage of Abeta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70 (2008) 2291-2298
13. Cummings J.L., Doody R., and Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 69 (2007) 1622-1634
14. Cummings J.L. Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Alzheimers & Dementia 2 (2006) 263-271
15. Leber P. Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord 10 (1996) 31-35
16. Leber P. Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis Assoc Disord 11 (1997) S10-S21
17. Blesa R., Davidson M., Kurz A., Reichman W., van Baelen B., and Schwalen S. Galantamine provides sustained benefits in patients with "advanced moderate" Alzheimer's disease for at least 12 months. Dement Geriatr Cogn Disord 15 (2003) 79-87
18. Horton S., Gutin A., and Hendrix S. A mathematical comparison of a "randomized withdrawal" clinical trial design and a parallel groups design to demonstrate disease modification in Alzheimer's disease (AD). Alzheimers & Dementia 3 (2007) S161
19. Siderowf A., and Stern M. Clinical trials with rasagiline: evidence for short-term and long-term effects. Neurology 66 (2006) S80-S88
20. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61 (2004) 561-566
21. Petersen R.C., Thomas R.G., Grundman M., Bennett D., Doody R., Ferris S., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352 (2005) 2379-2388
22. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: the Alzheimer's Disease Cooperative Study. N Engl J Med 336 (1997) 1216-1222
23. Vellas B., Andrieu S., Sampaio C., Coley N., and Wilcock G. European Task Force Group. Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 7 (2008) 436-450
24. Leber P. Draft guidelines for the clinical evaluation of antidementia drugs (1990), Food and Drug Administration, Rockville, MD
25. Cummings J.L. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 11 (2003) 131-145
26. Feigin A. Evidence from biomarkers and surrogate endpoints. NeuroRx 1 (2004) 323-330
27. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs?. JAMA 282 (1999) 790-795
28. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 1 (2004) 189-195
29. Lovestone S. Biomarkers in Alzheimer's disease. J Nutr Health Aging 10 (2006) 118-122
30. Morra J.H., Tu Z., Apostolova L.G., Green A.E., Avedissian C., Madsen S.K., et al. Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. Neuroimage 43 (2008) 59-68
31. Nestor S.M., Rupsingh R., Borrie M., Smith M., Accomazzi V., Wells J.L., et al. Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain 131 (2008) 2443-2454
32. Bobinski M., de Leon M.J., Wegiel J., Desanti S., Convit A., Saint Louis L.A., et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience 95 (2000) 721-725
33. Whitwell J.L., Josephs K.A., Murray M.E., Kantarci K., Przybelski S.A., Weigand S.D., et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 71 (2008) 743-749
34. Ridha B.H., Anderson V.M., Barnes J., Boyes R.G., Price S.L., Rossor M.N., et al. Volumetric MRI and cognitive measures in Alzheimer disease: comparison of markers of progression. J Neurol 255 (2008) 567-574
35. Jagust W. Molecular neuroimaging in Alzheimer's disease. NeuroRx 1 (2004) 206-212
36. Mega M.S., Cummings J.L., O'Connor S.M., Dinov I.D., Reback E., Felix J., et al. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol 14 (2001) 63-68
37. Mega M.S., Dinov I.D., Porter V., Chow G., Reback E., Davoodi P., et al. Metabolic patterns associated with the clinical response to galantamine therapy. Arch Neurol 62 (2005) 721-728
38. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., Mathis C.A., Price J.C., Tsopelas N.D., et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131 (2008) 1630-1645
39. Csernansky J.G., Miller J.P., McKeel D., and Morris J.C. Relationships among cerebrospinal fluid biomarkers in dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 16 (2002) 144-149
40. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59 (2006) 512-519
41. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005) 1553-1562
42. Grundman M., and Black R.S. O3-04-05: clinical trials of bapineuzumab, a beta-amyloid-targeted immunotherapy in patients with mild to moderate Alzheimer's disease. Alzheimers & Dementia 4 (2008) T166
43. Villemagne V.L., Pike K.E., Darby D., Maruff P., Savage G., Ng S., et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46 (2008) 1688-1697
44. Stomrud E., Hansson O., Blennow K., Minthon L., and Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord 24 (2007) 118-124
45. Apostolova L.G., Mosconi L., Thompson P.M., Green A.E., Hwang K.S., Ramirez A., et al. Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. Neurobiol Aging (2008) Sept 24 [Epub ahead of print]
46. Thal L.J., Kantarci K., Reiman E.M., Klunk W.E., Weiner M.W., Zetterberg H., et al. The role of biomarkers in clinical trials for Alzheimer's disease. Alzheimer Dis Assoc Disord 20 (2006) 6-15
47. Jack Jr. C.R., Petersen R.C., Xu Y.C., O'Brien P.C., Smith G.E., Ivnik R.J., et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52 (1999) 1397-1403
48. Archer H.A., Edison P., Brooks D.J., Barnes J., Frost C., Yeatman T., et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 60 (2006) 145-147
49. Jack Jr. C.R., Bernstein M.A., Fox N.C., Thompson P., Alexander G., Harvey D., et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 27 (2008) 685-691
50. Mueller S.G., Weiner M.W., Thal L.J., Petersen R.C., Jack C.R., Jagust W., et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers & Dementia 1 (2005) 55-66
51. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
52. Arvanitakis Z., Wilson R.S., Bienias J.L., Evans D.A., and Bennett D.A. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61 (2004) 661-666
53. Luchsinger J.A., Tang M.X., Shea S., and Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 63 (2004) 1187-1192
54. Cupples L.A., Farrer L.A., Sadovnick A.D., Relkin N., Whitehouse P., and Green R.C. Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med 6 (2004) 192-196
55. Launer L.J., Ross G.W., Petrovitch H., Masaki K., Foley D., White L.R., et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 21 (2000) 49-55
56. Honig L.S., Tang M.X., Albert S., Costa R., Luchsinger J., Manly J., et al. Stroke and the risk of Alzheimer disease. Arch Neurol 60 (2003) 1707-1712
57. Borstein Graves A., Mortimer J.A., Bowen J.D., McCormick W.C., McCurry S.M., Schellenberg G.D., et al. Head circumference and incident Alzheimer's disease. Neurology 57 (2001) 1453-1460
58. Schofield P.W., Logroscino G., Andrews H.F., Albert S., and Stern Y. An association between head circumference and Alzheimer's disease in a population-based study of aging and dementia. Neurology 49 (1997) 30-37
59. McIlroy S.P., Dynan K.B., Lawson J.T., Patterson C.C., and Passmore A.P. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 33 (2002) 2351-2356
60. Pappolla M.A., Bryant-Thomas T.K., Herbert D., Pacheco J., Fabra Garcia M., Manjon M., et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61 (2003) 199-205
61. Shobab L.A., Hsiung G.Y., and Feldman H.H. Cholesterol in Alzheimer's disease. Lancet Neurol 4 (2005) 841-852
62. Kivipelto M., Ngandu T., Laatikainen T., Winblad B., Soininen H., and Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 5 (2006) 735-741
63. ADAPT Research Group, Martin B.K., Szekely C., Brandt J., Piantadosi S., Breitner J.C., et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65 (2008) 896-905